Welcome to Biogen Australia and New Zealand
Biogen Idec (NASDAQ: BIIB) is now known as Biogen. This change applies to all of Biogen’s global affiliates.
Biogen remains the same. This change reflects our heritage, our evolution as a company and our future. Focus and the continued rigorous commitment to science has been core to Biogen. Founded in 1978, Biogen is the world’s oldest independent biotechnology company and patients worldwide benefit from its advanced multiple sclerosis and innovative haemophilia therapies.
Our mission remains the same. We continue to be a company firmly based in science, focused on patients and determined to bring forward important new medicines in areas of unmet medical need. Biogen discovers, develops and delivers to patients worldwide, innovative therapies for the treatment of neurodegenerative diseases, haematologic conditions and autoimmune disorders.
Through cutting-edge science and medicine, Biogen and IDEC merged in 2003 to create Biogen Idec. Since that time the company has seen significant growth as a provider of therapies for multiple sclerosis and haemophilia. IDEC brought two important contributions of cancer treatments to the combined organization. In 2010, Biogen transferred its research and commercial focus away from oncology to three core areas: neurology, immunology and haematology.
We have a long‐standing heritage in multiple sclerosis (MS), having developed more therapies than any other company. While we are still focused on developing new treatments for MS, we have shifted into other serious diseases in our core areas of focus, such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, lupus nephritis and neuropathic pain. Our product development in early and mid‐stage pipeline includes potential candidates for serious and difficult‐to‐treat neurodegenerative diseases and fibrotic and nonmalignant blood disorders.